Click here to learn about Academy events, publications and initiatives around COVID-19.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Support The World's Smartest Network
×

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

DONATE
This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Targeting the Endocannabinoid System for Treatment of Human Diseases

Targeting the Endocannabinoid System for Treatment of Human Diseases

Wednesday, January 27, 2021, 8:30 AM - 6:00 PM EST

The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York

Presented By

The New York Academy of Sciences

 

The endocannabinoid system (ECS) maintains homeostasis in the body by regulating physiologic processes including neurotransmission, mood, energy balance, immune responses, and wound healing. Functions of the ECS are mediated by two cannabinoid receptors, Type 1 and 2 (CB1 and CB2). This meeting will focus on the understanding of the physiology and pharmacology of the peripheral endocannabinoid system. The goal is to illuminate the roles of CB1 and CB2 receptors with regard to possible discovery and development of entirely new classes of drugs for the treatment of inflammatory, immune, and fibrotic disorders.

Call for Abstracts

Abstract submissions are invited for a poster session. For complete submission instructions, please visit our online portal. The deadline for abstract submission is Friday, November 20, 2020.

Registration

Member
By 12/18/2020
$90
After 12/18/2020
$130
Nonmember Academia, Faculty, etc.
By 12/18/2020
$180
After 12/18/2020
$260
Nonmember Corporate, Other
By 12/18/2020
$250
After 12/18/2020
$350
Nonmember Not for Profit
By 12/18/2020
$180
After 12/18/2020
$260
Nonmember Student, Undergrad, Grad, Fellow
By 12/18/2020
$100
After 12/18/2020
$145
Member Student, Post-Doc, Fellow
By 12/18/2020
$50
After 12/18/2020
$70
Earlybird Registration:
82
days
left
Deadline:
54
days
left

Scientific Organizing Committee

Sonya Dougal, PhD

The New York Academy of Sciences

Allyn Howlett, PhD

Wake Forest School of Medicine

George Kunos, MD, PhD

National Institute on Alcohol Abuse and Alcoholism

Barbara White, MD

Corbus Pharmaceuticals

George Zavoico, PhD

B. Riley FBR

Speakers

Derek W. Gilroy, PhD

University College London

Cecilia J. Hillard, PhD

Medical College of Wisconsin

Andrea Hohmann, PhD

Indiana University Bloomington

Allyn C. Howlett, PhD

Wake Forest School of Medicine

Aron H. Lichtman, PhD

Virginia Commonwealth University

George Kunos, MD, PhD

National Institute on Alcohol Abuse and Alcoholism

Kenneth Mackie, MD

Indiana University

Kathryn Nichol, PhD

Greenwich Biosciences

Barbara White, MD

Corbus Pharmaceuticals

Friday

June 19, 2020

8:30 AM

Registration / Check-in / Breakfast

9:00 AM

Opening Remarks

9:15 AM

Biology and Pharmacology of Endocannabinoid System

Speaker

Allyn Howlett
Wake Forest School of Medicine

Session 1: CB1

Session Chairperson
George Kunos, MD, PhD, National Institute on Alcohol Abuse and Alcoholism
10:00 AM

TBD

Speaker

George Kunos, MD, PhD
National Institute on Alcohol Abuse and Alcoholism
10:30 AM

TBD

Speaker

Kathryn Nichol, PhD
Greenwich Biosciences
11:00 AM

Coffee Break

11:20 AM

Cannabinoids for Weight Loss: A Twisted Tale

Speaker

Kenneth Mackie, MD
Indiana University

Cannabis stimulates consumption of calorically dense, nutritionally poor food (AKA “the munchies”). Surprisingly, most epidemiological studies have found an association between chronic cannabis use and reduced body weight, central obesity, and risk for type II diabetes, despite a poor diet. To understand the metabolically protective effects of cannabis, we have investigated THC’s interactions with

GPR119, a nutrient-sensing G protein coupled receptor, found in pancreas and the gut. GPR119 activation by partially digested lipids increases insulin secretion and sensitivity, preserves beta cell mass, and enhances incretin secretion. GPR119 signaling was assessed in HEK293 cells stably expressing GPR119 and GluTag cells endogenously expressing GPR119. Wildtype C57BL/6J and GPR119 knockout mice were made obese by a high fat diet (HFD). Mice were treated with vehicle or various drugs and their weights recorded.

1) THC and its metabolites activated GPR119 in a functionally-selective fashion, 2) THC and its metabolites increased GLP-1 secretion from GluTag cells, 3) THC, administered intraperitoneally or orally, induced reversible weight loss in obese wildtype, but not GPR119 KO mice, 4) THC administered to adolescent mice, concurrently with a HFD, attenuated HFD-induced weight gain.

These results suggest that sustained use of cannabis might activate GPR119, leading to weight loss (or attenuated weight gain), increased incretin secretion and an overall improvement in metabolic health.

Coauthors: Amey Dhopeshwarkar, Parhesh Kumar, and Jim Wager-Miller, Indiana University.

11:50 AM

TBD

Speaker

Aron H. Lichtman, Ph.D.
Virginia Commonwealth University
12:20 PM

Panel Discussion

Speakers

Moderator: George Kunos, MD, PhD
National Institute on Alcohol Abuse and Alcoholism
Kathryn Nichol, PhD
Greenwich Biosciences
Kenneth Mackie, MD
Indiana University
Aron H. Lichtman, PhD
Virginia Commonwealth University
12:50 PM

Lunch Break & Poster Session

Session 2: CB2

Session Chairperson
Cecilia J. Hillard, PhD, Medical College of Wisconsin
2:20 PM

Novel Mechanism for the Regulation of Endocannabinoid Signaling

Speaker

Cecilia J. Hillard, PhD
Medical College of Wisconsin
2:50 PM

New Insights into the Resolution of Acute Inflammation in Humans Provided by Lenabasum, a Synthetic Analogue of delta -8- tetrahydrocannabinol (THC)-11-oic Acid

Speaker

Derek Gilroy, PhD
University College London

The current therapeutic strategy for treating chronic inflammatory diseases is based largely upon inhibiting the factors that drive acute inflammation and include nonsteroidal anti-inflammatory drug, steroids and biologics. Although these medicines ameliorate some disease symptoms, they do not bring about a ‘cure’. Thus, there is a significant need to identify more effective and safer therapeutics to treat chronic inflammatory diseases. One emerging approach is to harness the body’s own inflammatory resolution process for therapeutic gain. Lenabasum is a synthetic analogue of delta -8- tetrahydrocannabinol (THC)-11-oic acid that in pre-clinical models of experimental inflammation exerts potent anti-inflammatory actions with minimal CNS cannabimimetic activity. Using a model of acute inflammation driven by i.d. UV-killed E. coli in healthy humans we found that Lenabasum exerted a potent anti-inflammatory effect equivalent to that of prednisolone in terms of inhibiting neutrophil infiltration, the hallmark of acute inflammation. These effects arose from the inhibition of the neutrophil chemoattractant LTB4, while the inhibition of anti-phagocytic prostanoids (PGE2,) resulted in enhanced clearance of inflammatory stimulus from the injected site. One striking observation that we made was the Lenabasum may trigger the synthesis of endogenous gases synonymous with proresolution of inflammation. In this presentation we will provide an update on this are of research and present a novel pathway for the resolution of diseases driven by chronic inflammation in humans.

Coauthors: James Glanville and Madhur P. Motwani, University College London; and Barbara White, Corbus Pharmaceuticals.

3:20 PM

TBD

Speaker

Andrea Hohmann, PhD
Indiana University Bloomington
3:50 PM

TBD

Speaker

Barbara White, MD
Corbus Pharmaceuticals
4:20 PM

Coffee Break

4:40 PM

Panel Discussion

Speakers

Moderator: Allyn Howlett, PhD
Wake Forest School of Medicine
Cecilia J. Hillard, PhD
Medical College of Wisconsin
Derek Gilroy, PhD
University College London
Andrea Hohmann, PhD
Indiana University Bloomington
Barbara White, MD
Corbus Pharmaceuticals
5:10 PM

Closing Remarks

5:15 PM

Networking Reception

6:00 PM

Adjourn